Development of Chronic Bronchitis and Emphysema in β-Epithelial Na + Channel–Overexpressing Mice

Chronic obstructive pulmonary disease is a leading cause of death worldwide, but its pathogenesis is not well understood. Previous studies have shown that airway surface dehydration in beta-epithelial Na(+) channel (betaENaC)-overexpressing mice caused a chronic lung disease with high neonatal pulmo...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of respiratory and critical care medicine Vol. 177; no. 7; pp. 730 - 742
Main Authors Mall, Marcus A., Harkema, Jack R., Trojanek, Joanna B., Treis, Diana, Livraghi, Alessandra, Schubert, Susanne, Zhou, Zhe, Kreda, Silvia M., Tilley, Stephen L., Hudson, Elizabeth J., O'Neal, Wanda K., Boucher, Richard C.
Format Journal Article
LanguageEnglish
Published New York, NY American Lung Association 01.04.2008
American Thoracic Society
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Chronic obstructive pulmonary disease is a leading cause of death worldwide, but its pathogenesis is not well understood. Previous studies have shown that airway surface dehydration in beta-epithelial Na(+) channel (betaENaC)-overexpressing mice caused a chronic lung disease with high neonatal pulmonary mortality and chronic bronchitis in adult survivors. The aim of this study was to identify the initiating lesions and investigate the natural progression of lung disease caused by airway surface dehydration. Lung morphology, gene expression, bronchoalveolar lavage, and lung mechanics were studied at different ages in betaENaC-overexpressing mice. Mucus obstruction in betaENaC-overexpressing mice originated in the trachea in the first days of life and was associated with hypoxia, airway epithelial necrosis, and death. In surviving betaENaC-overexpressing mice, mucus obstruction extended into the lungs and was accompanied by goblet cell metaplasia, increased mucin expression, and airway inflammation with transient perinatal increases in tumor necrosis factor-alpha and macrophages, IL-13 and eosinophils, and persistent increases in keratinocyte-derived cytokine (KC), neutrophils, and chitinases in the lung. betaENaC-overexpressing mice also developed emphysema with increased lung volumes, distal airspace enlargement, and increased lung compliance. Our studies demonstrate that airway surface dehydration is sufficient to initiate persistent neutrophilic airway inflammation with chronic airways mucus obstruction and to cause transient eosinophilic airway inflammation and emphysema. These results suggest that deficient airway surface hydration may play a critical role in the pathogenesis of chronic obstructive pulmonary diseases of different etiologies and serve as a target for novel therapies.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Supported by Marie Curie Excellence Grant from the European Commission (MEXT-CT-2004–013666 to M.A.M.), the Deutsche Forschungsgemeinschaft (DFG MA 2,081/3–2 to M.A.M.), the North American Cystic Fibrosis Foundation (MALL04G0 to M.A.M. and R026-CR02 to W.K.O.), and the National Institutes of Health (NIH SCOR P50 HL60280, P01 HL34322, and MTCC P30 DK065988 to R.C.B.).
This article has an online supplement, which is accessible from this issue's table of contents at www.atsjournals.org
Conflict of Interest Statement: M.A.M is listed on a patent application filed by the University of North Carolina at Chapel Hill, describing the βENaC-overexpressing mouse. The βENaC-overexpressing mouse has been deposited at JAX for general disposition. J.R.H. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. J.B.T. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. D.T. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. A.L. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. S.S. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. Z.Z. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. S.M.K. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. S.L.T. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. E.J.H. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. W.K.O. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. R.C.B. is listed on a patent application filed by the University of North Carolina at Chapel Hill describing the βENaC-overexpressing mouse.
Correspondence and requests for reprints should be addressed to Marcus A. Mall, M.D., Pediatric Pulmonology and Cystic Fibrosis Center, Department of Pediatrics III, University of Heidelberg, Im Neuenheimer Feld 153, 69120 Heidelberg, Germany. E-mail: marcus.mall@med.uni-heidelberg.de
Originally Published in Press as DOI: 10.1164/rccm.200708-1233OC on December 13, 2007
ISSN:1073-449X
1535-4970
1535-4970
DOI:10.1164/rccm.200708-1233OC